{
    "clinical_study": {
        "@rank": "74110", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Determine whether high-dose intravenous immune globulin (IVIG) is more\n      effective than placebo in restoring neurologic function (muscle strength) in patients with\n      multiple sclerosis.\n\n      II.  Determine the time to recovery following IVIG."
        }, 
        "brief_title": "Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis", 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are treated with\n      intravenous immune globulin or placebo.  In the absence of a hypersensitivity reaction to a\n      test dose, a total of 11 doses is administered:  daily for 5 days, then every 2 weeks for 12\n      weeks.\n\n      Patients are followed at 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Clinically or laboratory-supported definite multiple sclerosis\n\n          -  Disease relapsing-remitting or relapsing-progressive (i.e., secondary- progressive)\n\n          -  Targeted neurologic deficit as follows: 25% or more loss of power in at least 1 limb\n             Severity -1 or greater on Mayo Clinic rating scale OR Between 3+/5 and 4-/5 on\n             Medical Research Clinic muscle power scale\n\n          -  Documented by Mayo Clinic Department of Neurology as neither progressing nor\n             improving for 4 to 18 months prior to entry No clinical evidence of spontaneous or\n             corticosteroid-induced improvement\n\n          -  Able to cooperate with isometric strength testing requirements\n\n        --Prior/Concurrent Therapy--\n\n          -  No concurrent experimental drug therapy\n\n          -  No concurrent intravenous immune globulin At least 3 months since immunosuppressive\n             therapy, e.g., corticosteroids and corticotropin\n\n          -  At least 3 months since plasma exchange\n\n        --Patient Characteristics--\n\n          -  Hepatic: No coagulation defect, e.g., hyperviscosity syndrome\n\n          -  Renal: Creatinine no greater than 1.5 times normal\n\n          -  Cardiovascular: No unstable or advanced ischemic or cerebrovascular disease, e.g.:\n             angina congestive heart failure transient ischemic attack stroke\n\n          -  Immunologic: No human gamma globulin or albumin sensitivity No hypergammaglobulinemia\n             No known antibody deficiency syndrome, especially IgA deficiency\n\n        Other:\n\n          -  No condition interfering with neurologic exam, e.g.:\n\n          -  Major amputation\n\n          -  Deforming arthritis\n\n          -  Major psychiatric illness\n\n          -  Superimposed lower motor neuron deficit\n\n          -  No intellectual impairment precluding study participation\n\n          -  No pregnant or nursing women\n\n          -  Adequate contraception required of fertile patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "76", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004744", 
            "org_study_id": "199/11660", 
            "secondary_id": "MAYOC-27992"
        }, 
        "intervention": {
            "intervention_name": "immune globulin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "keyword": [
            "multiple sclerosis", 
            "neurologic and psychiatric disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "September 8, 2008", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "John H. Noseworthy", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 1998", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004744"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Neurological Disorders and Stroke (NINDS)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "February 1993", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2008"
    }, 
    "geocoordinates": {}
}